Evaluation of LamPORE rapid tests for Covid-19 show high levels of diagnostic sensitivity | University of Oxford

Evaluation of LamPORE rapid tests for Covid-19 show high levels of diagnostic sensitivity

25 September 2020

Scientists from the University of Oxford’s Nuffield Department of Medicine have today published their evaluation of LamPORE, a novel diagnostic platform for detecting SARS-CoV-2 RNA. It combines loop-mediated isothermal amplification with nanopore sequencing. This technology has the potential to analyse thousands of samples per day on a single instrument.

The collaboration between colleagues at Public Health England Porton Down (PHE), the University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust and the University of Oxford including support from the NIHR Oxford Biomedical Research Centre, evaluated the performance of LamPORE against RT-PCR - the most commonly-used laboratory test for Covid-19. They used RNA extracted from two types of samples. Initially, mock samples formed of saliva from people without infection that had a known quantity of virus added to it, and subsequently nose and throat swabs from real Covid-19 patients collected during routine care at two UK hospitals - Oxford University Hospitals NHS Foundation Trust and Sheffield Teaching Hospitals NHS Foundation Trust.

The positive clinical specimens came mostly from patients with symptomatic infection, and among these LamPORE had a diagnostic sensitivity of 99.1% (i.e. it was positive in 226 of 228 samples positive by RT-PCR). Among negative clinical specimens, including 153 with other respiratory pathogens detected, LamPORE had a diagnostic specificity of 99.6% (i.e. it was negative in 278 of 279 samples negative by RT-PCR). Overall, 1.4% of samples produced an indeterminate result on first testing, and repeat LamPORE testing on the same RNA extract had a reproducibility of 96.8%.

These results indicate that LamPORE has a similar performance to RT-PCR for the diagnosis of SARS-CoV-2 infection in symptomatic patients.
Professor Derrick Crook, from the Nuffield Department of Medicine, University of Oxford, who led the evaluation, said: ‘This evaluation shows that LamPORE offers a promising approach to high-throughput testing.’

Dr Steve Pullan, from Public Health England, Porton Down, said: ‘Our early data indicates LamPORE to be a credible alternative to conventional PCR -based diagnostics, which has the potential to provide further high-throughput testing capacity.’

Prof Helen McShane, Director of the NIHR Oxford BRC, said: ‘Oxford’s expertise in clinical microbiology and pathogen sequencing has been combined with state-of-the-art sequencing technology from Oxford Nanopore to generate this really important data. This is an excellent example of how NIHR funding to support academic–industrial collaborations can lead to the development of new tools to help us control the SARS-CoV-2 pandemic.’
Dr Cariad Evans, Consultant Virologist at Sheffield Teaching Hospitals NHS Foundation Trust and joint senior author of the published evaluation, said: ’We are pleased to have contributed to this important evaluation. These are encouraging early findings and we are proud to have supported Public Health England and our academic partners in this essential Covid-19 research.’

About LamPORE

The LamPORE test uses standard Oxford Nanopore Technologies flow cells compatible with the desktop GridION device and palm-sized MinION Mk1C device. It has the potential to be used both for distributed and centralised laboratory Covid-19 testing.
The protocol currently allows up to 96 samples to be analysed on one flow cell, potentially allowing thousands of samples to be analysed per day on a single instrument. The workflow involves a 40-minute amplification, followed by a library preparation and a 60-minute sequencing run, generating results in a comparable time to RT-PCR when starting with extracted RNA.

Limitations

Where LamPORE does not detect SARS-CoV-2 in a positive sample, the study found that this happened mostly in weak positives with low levels of virus. These might be more common if the test were used only on people with mild or asymptomatic infection. The evaluation was conducted after the first wave of Covid-19 in the UK, when there were few new cases, so the scientists relied on frozen samples, which could differ from fresh ones.
The scientists did not evaluate how the throughput and turnaround time of LamPORE would compare to RT-PCR during routine use in a clinical laboratory or centralised testing centre.

Potential use

Using LamPORE for high-throughput testing of tens or hundreds of thousands of samples per day is dependent on a streamlined workflow, including automated sample handling and integration with laboratory information management systems.
The scientists conclude that LamPORE on extracted RNA offers a promising method of high throughput SARS-CoV-2 testing. It could be of much broader use if shown to work with extraction-free methods of sample preparation and automated workflows.

Read the full paper on the pre-print server, medrxiv here: https://medrxiv.org/content/10.1101/2020.09.18.20195370v1

For further information please contact: news.office@admin.ox.ac.uk 

Notes to Editors: 

Funding: This work was supported by the Department of Health and Social Care, the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in partnership with PHE Porton Down, and the NIHR Oxford Biomedical Research Centre. 

The University of Oxford 
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions. 

Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield Teaching Hospitals is one of the UK’s largest NHS Foundation Trusts and one of the largest and busiest teaching hospitals. We have over 17,800 staff caring for over two million patients each year at our five hospitals and in the local community. The Trust is a recognised leader in medical research for bone, cardiac, neurosciences and long term conditions such as diabetes and lung disease. We also play a key role in the training and education of medical, nursing and dental students with our academic partners, including the University of Sheffield and Sheffield Hallam. The Trust is a recognised leader in healthcare innovation and is host to a number of national projects Devices for Dignity, Yorkshire and Humber Genomics Centre as well as being a partner in the South Yorkshire and Bassetlaw Integrated Care System and the National Centre for Sports and Exercise Medicine. 

The University of Sheffield
With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities. A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines. Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in. Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields. Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations. 

The National Institute for Health Research (NIHR)Oxford Biomedical Research Centre (BRC) is based at the Oxford University Hospitals NHS Foundation Trust and run in partnership with the University of Oxford. 
The NIHR is the nation's largest funder of health and care research. The NIHR: 

  • Funds, supports and delivers high quality research that benefits the NHS, public health and social care 
  • Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research 
  • Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future 
  • Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services 
  • Partners with other public funders, charities and industry to maximise the value of research to patients and the economy 

The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government. 
This work uses data provided by patients and collected by the NHS as part of their care and support and would not have been possible without access to this data. The NIHR recognises and values the role of patient data, securely accessed and stored, both in underpinning and leading to improvements in research and care. www.nihr.ac.uk/patientdata

PHE 
PHE exists to protect and improve the nation's health and wellbeing and reduce health inequalities. It does this through world-leading science, research, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health. It provides government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support.